Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th
Published on: Friday, September 22nd, 2017 View all Media
RUTHERFORD, N.J., September 22, 2017– Cancer Genetics, Inc. (Nasdaq: CGIX, the Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced it will be presenting at this year’s Disruptive Growth Company Showcase on September 27th in New York City.
John A. (Jay) Roberts, Chief Operating Officer and EVP, Finance of CGI, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
2017 Disruptive Growth Company Showcase NYC – Cancer Genetics, Inc. Presentation
Date: Wednesday, September 27, 2017
Time: 1:30 pm Eastern Time
Location: Grand Hyatt New York
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.